Author(s):
Aparna Desai, Ashish Pagariya, Monika Rathod, Kalyani Kayande, Mahavir Chhajed, Rushali Deokar, Sudhish Rai
Email(s):
ashishpagariya@gmail.com
DOI:
10.52711/0974-360X.2024.00322 
Address:
Aparna Desai1, Ashish Pagariya1, Monika Rathod1, Kalyani Kayande2, Mahavir Chhajed3, Rushali Deokar4, Sudhish Rai5
1Department of Pharmacognosy, Bhartiya Education Society’s Institute of Pharmacy, Velshet (Nagothane), Dist: Raigad.
2Department of Pharmaceutics, Sinhgad Institute of Pharmacy, Narhe, Pune, Maharashtra, India 411041.
3Vikrant Institute of Pharmacy and Science, Indore.
4Department of Pharmaceutics, Jaihind College of Pharmacy, Junnar, Pune.
5Jagrani Devi Pharmacy College, Baradwar, Shakti.
*Corresponding Author
Published In:
Volume - 17,
Issue - 5,
Year - 2024
ABSTRACT:
The present work aimed to formulate and evaluate Besifloxacin Hydrochloride (HCl) ophthalmic in situ gel for conjunctivitis, based on temperature triggered gelation system to increase ocular residence time, bioavailability and patient compliance. Different formulations were prepared by using Poloxamer 407 and Poloxamer 188 as temperature sensitive as well as mucoadhesive polymers. Design expert software version 11 was used to optimized the formula. Optimized batch having Poloxamer 407 (24.80% w/v) and Poloxamer 188 (14.53% w/v) was evaluated for visual appearance, clarity, gelation temperature, gelling capacity, rheological property, ex vivo, in vitro release and accelerated stability studies. Histopathological study was carried out using Goat cornea and revealed no change in histopathology of the tissues. Formulation was found to be effective against the Escherichia coli and Staphylococcus aureus. Cumulative % drug release of Besifloxacin HCl ophthalmic in situ gel after 8 hours was found to be 96.47 %.
Cite this article:
Aparna Desai, Ashish Pagariya, Monika Rathod, Kalyani Kayande, Mahavir Chhajed, Rushali Deokar, Sudhish Rai. Besifloxacin HCl Ophthalmic In situ Gel: Design, Optimization, In vitro and Ex vivo Investigation. Research Journal of Pharmacy and Technology. 2024; 17(5):2035-9. doi: 10.52711/0974-360X.2024.00322
Cite(Electronic):
Aparna Desai, Ashish Pagariya, Monika Rathod, Kalyani Kayande, Mahavir Chhajed, Rushali Deokar, Sudhish Rai. Besifloxacin HCl Ophthalmic In situ Gel: Design, Optimization, In vitro and Ex vivo Investigation. Research Journal of Pharmacy and Technology. 2024; 17(5):2035-9. doi: 10.52711/0974-360X.2024.00322 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2024-17-5-18
REFERENCES:
1. A. Hugo, S. Maria, Lobao and L. Jose, In situ gelling system: a strategy to improve the bioavailability of ophthalmic pharmaceutical formulations. Drug Discov. Today. 2014: 1-13, 10.1016/j.drudis.2013.10.001.
2. Anil G, Rama A, Thirupathi G, Ramesh B. Topical ophthalmic in situ gels for ocular delivery: A recent Update. Saudi J. Med. Pharm. Sci. 2017; 3(7B): 804-807.
3. L. Li, D. Guo, Guo J, Song J, Wu Q, Liu D, Bia H, Xi. Thermosensitive in-situ forming gels for ophthalmic delivery of tea polyphenols. J. Drug Delivery Sci. Technol. 2018; 46: 243–250, 10.1016/j.jddst.2018.05.019.
4. Qian Y, Wang F, Li R, Zhang Q, and Xu Q. Preparation and evaluation of in situ gelling ophthalmic drug delivery system for methazolamide. Drug. Dev. Ind. Pharm. 2010; 36(11): 1340–1347, 10.3109/03639041003801893.
5. Sharadha M, Gowda D, Vishal G, and Bhavya M. Fabrication, Characterization and Evaluation of In Situ Gel for the Treatment of Conjunctivitis. J. Pharm. Sci. Res. 2018; 10(5): 1220-1222.
6. Panchal V, Chilkwar R, Saboji J, Patil S, and Nanjwade B. Development and Evaluation Ophthalmic In Situ Gel of Betaxolol HCl by Temperature Dependent Method for Treatment of Glaucoma. J. Pharm. Sci. Pharmacol. 2015; 2: 21–25, 10.1166/jpsp.2015.1043.
7. Srividya B, Cardoza R, Amin P. Sustained ophthalmic delivery of ofloxacin from a pH triggered in situ gelling system. J. Control. Release. 2001; 73: 205–211.
8. Saher O, Ghorab D, and Mursi N. Preparation and in vitro/in vivo evaluation of antimicrobial ocular in situ gels containing a disappearing preservative for topical treatment of bacterial conjunctivitis. Pharm. Dev. Technol. 2015: 1-11, 10.3109/10837450.2015.1035728.
9. Khan N, Aqil M, Imam S, and Ali A. Development and evaluation of a novel in situ gel of sparfloxacin for sustained ocular drug delivery: in vitro and ex vivo characterization. Pharm. Dev. Technol. 2014: 1-8, 10.3109/10837450.2014.910807.
10. Geethalakshmia A, Roopa K, Poornima S, Sajal Kumar J, Venkatesh.P. Temperature Triggered In situ Gelling System for Betaxolol in Glaucoma. J. Appl. Pharm. Sci. 2013; 3(2): 153-159. 10.7324/JAPS.2013.30227.
11. Sirish V, Sadhna K, Nalini S, and Sadanandam M. Development and evaluation of thermoreversible ocular gels of ketorolac tromethamine. Int. J. Biopharm. 2010; 1(1): 39-45.
12. Rajalakshmi R, Padaja C, Radhika N, Kumuda P, Pavan Kumar P, Ujjwala B, and Vinesha V, Formulation and assessment of gemifloxacin mysylate ocular in situ gelling system. Int. Res. J. Pharm. 2013; 4(10): 33-38. 10.7897/2230-8407.041009.